If you think healthcare sector stocks might be your next investment move, you are in the right place. From the sector’s risks and benefits to its historic performance, here is everything you need to know.
The healthcare sector comprises a range of subsectors, from pharmaceuticals and biotechnology to insurers and retailers, making it one of the largest and most complex sectors of the economy.
In this guide, you will learn about the many industries that comprise the healthcare sector, the investment opportunities available, and what to watch out for as you invest.
What Is the Healthcare Sector?
The healthcare sector encompasses businesses that provide medical services, manufacture medical equipment, develop pharmaceuticals, and offer health insurance. This vast sector touches every aspect of human health and wellbeing, making it a cornerstone of the global economy.
Healthcare stocks belong to the healthcare sector of the stock market and consist of a number of industries that can be broken down into the following:
This includes hospitals, nursing homes, health facilities and laboratories.
This refers to businesses that provide and underwrite health insurance policies.
Medical equipment companies create and manufacture equipment that is used across the health sector such as surgical masks, pacemakers and stethoscopes.
ceuticals.
Biotechnology and pharmaceutical firms research and develop drugs and vaccines.
The healthcare sector’s diversity means investors can choose from companies with different risk profiles and growth potential. A dividend from a stable pharmaceutical company differs vastly from the growth potential of an emerging biotech firm.
This variety in company structure opens up possibilities to use healthcare stocks to build a well-rounded investment portfolio. But investors should be aware of to what extent key price drivers will influence each sector and individual company.
Performance and volatility varies depending on factors such as:
- Government regulation
- Scientific and technological developments
- Changing demographics.
Is the Healthcare Sector Worth Investing In?
The sector’s fundamental strength lies in its essential nature – healthcare services remain in demand regardless of economic conditions.
Individual stocks will have different risk profiles. Some offer growth potential while stocks of strong and reputable healthcare companies can provide a degree of stability in an investment portfolio. Here are a few reasons why it could be worth investing in the sector.
- Inelastic Demand and Demographic Trends: Ageing populations create increasing demand for pharmaceuticals, medical devices, and healthcare services.
- Innovation and Technological Advancement: From AI-powered diagnostics to personalised medicine, technological breakthroughs create new investment opportunities.
- Investment in digital health: Digital healthcare, also known as telehealth and eHealth, has seen substantial growth during the pandemic, and is expected to keep growing with the global market expected to be worth $900bn by 2030.
Tip: Consider healthcare Exchange-Traded Funds (ETFs) which offer instant diversification across multiple healthcare subsectors.
How Have Healthcare Stocks Performed Historically?
Healthcare stocks have demonstrated impressive resilience and growth over the past decade. The MSCI World Health Care Index has outperformed the broader market in many periods, showcasing the sector’s strength.
Recent Performance and Market Dynamics
Healthcare stocks recovered strongly from pandemic-related disruptions. While elective procedures were postponed in 2020-2021, the sector has rebounded as healthcare systems normalised. Pharmaceutical companies particularly benefited from vaccine development and increased focus on healthcare innovation.
Long-term Growth Drivers
Biotechnology advances have accelerated, with breakthrough treatments for previously untreatable conditions reaching the market. The success of mRNA vaccine technology has opened new avenues for drug development, potentially revolutionising treatment for various diseases.
What Are the Benefits of Investing in Healthcare Stocks?
Healthcare stocks offer UK investors exposure to an essential, innovative sector with both defensive qualities and significant growth potential. There are the other potential benefits of investing in the healthcare sector.
Diversification Opportunities
The sector’s breadth allows investors to spread risk across different industries with varying growth profiles. A balanced healthcare portfolio might include stable pharmaceutical giants alongside innovative biotech firms and essential medical device manufacturers.
Defensive Characteristics
Low volatility healthcare stocks might appear more attractive during market volatility. People require medical care regardless of economic conditions, providing healthcare companies with relatively stable revenue streams.
Innovation and Growth Potential
Healthcare companies consistently invest heavily in research and development, with annual global pharmaceutical R&D spending forecast to exceed $350bn by 2030. This investment drives innovation that can lead to significant returns for patient investors.
What Risks Are Involved in Investing in Healthcare Stocks?
While healthcare offers substantial opportunities, investors must understand the sector’s unique risks.
Regulatory Challenges
Healthcare is among the most heavily regulated industries globally. Organisations such as the Medicines and Healthcare products Regulatory Agency (MHRA) oversee drug approvals and medical device safety. Regulatory changes can impact company profits and growth prospects substantially.
Clinical Trial Risks
These particularly affect pharmaceutical and biotechnology companies. Approximately 90% of drugs entering clinical trials fail to receive approval. This high failure rate means investors in early-stage biotech companies face substantial risk, though successful drugs can generate exceptional returns.
Competition and Pricing Pressures
Generic drug competition, government pricing negotiations, and insurance reimbursement changes can significantly impact company revenues. Patent expirations for blockbuster drugs create “patent cliffs” that can dramatically affect pharmaceutical company earnings.
Tip: Research a company’s drug pipeline and patent expiration dates before investing in pharmaceutical stocks.
What’s Next for Healthcare Stocks?
The healthcare sector stands at an interesting inflection point, with multiple trends setting up to potentially shape its future trajectory.
Emerging Technologies and Treatments
Wider technological advances promise to transform healthcare delivery. Artificial intelligence accelerates drug discovery, potentially reducing development timelines from decades to years. Gene therapy and personalised medicine offer targeted treatments based on individual genetic profiles.
Global Health Initiatives
Increasing healthcare access in emerging markets creates growth potential for established healthcare companies. The World Health Organisation estimates that universal health coverage could add millions of new patients to the global healthcare system by 2030.
Sustainability and ESG Considerations
Companies focusing on affordable medicines, equitable access, and environmental sustainability attract growing investor interest from investors with an ESG viewpoint. This shift towards responsible investing creates opportunities for companies aligning profit with purpose.
Who Are the Big Players in Healthcare Stocks?
Several industry giants dominate the global healthcare landscape, offering investors exposure to established market leaders.
Johnson & Johnson (JNJ)
stands as a healthcare conglomerate with diversified operations spanning pharmaceuticals, medical devices, and consumer products. Founded in 1886, the company’s stable dividend history and broad product portfolio make it a popular choice for conservative investors.
Past performance is not an indication of future results.
AstraZeneca (AZN)
The UK-based pharmaceutical giant, focuses on oncology, cardiovascular, and respiratory treatments. As a FTSE 100 constituent, it offers UK investors domestic exposure to global markets. The company’s strong drug pipeline and commitment to innovation position it well for future growth.
Past performance is not an indication of future results.
Novo Nordisk (NOVO-B)
Novo leads in diabetes care and obesity treatments. The Danish company’s GLP-1 drugs for weight management have captured significant market attention, driving substantial share price appreciation. This success demonstrates how breakthrough treatments can transform company valuations.
Past performance is not an indication of future results.
Final thoughts
The healthcare sector is undergoing a powerful transition away from being regarded as a defensive sector to a high-growth, innovation-led, investment opportunity. A situation helped by the more stable regulatory environment which has cleared the policy clouds that previously weighed on valuations.
With some healthcare stocks trading at a historical discount relative to the broader market, the sector is widely viewed by analysts as having potential to “play catch-up”. However, thorough research would need to be conducted to establish how pharmaceutical stocks fit in with your portfolio.
Visit the eToro Academy to learn more about investing in specific sectors.
Frequently Asked Questions
- What percentage of my portfolio should I allocate to healthcare stocks?
-
Financial advisers typically recommend healthcare stocks comprise 10-15% of a diversified portfolio. However, your specific allocation should depend on your risk tolerance, investment timeline, and overall financial goals. Consider your existing exposure through pension funds or other investments when determining your healthcare allocation.
- Should I invest in individual healthcare stocks or healthcare ETFs?
-
Healthcare ETFs (Exchange Traded Funds) offer instant diversification and professional management, making them suitable for beginners or those seeking broad sector exposure. Individual stocks provide opportunities for higher returns but require more research and carry greater risk. Many investors combine both approaches for balanced exposure.
- How do drug patent expirations affect pharmaceutical stock prices?
-
Patent expirations, known as “patent cliffs,” can significantly impact pharmaceutical companies when generic competitors enter the market. Share prices often decline in anticipation of lost revenue. However, companies with strong drug pipelines and new product launches can offset these losses. Research upcoming patent expirations before investing.
- How has the One Big Beautiful Bill Act (OBBBA) impacted healthcare stocks?
-
The OBBBA has provided much-needed clarity for the healthcare sector by allowing for the immediate expense of R&D costs rather than long-term amortisation. This has boosted the net income of innovation-heavy biotech and pharmaceutical firms. Additionally, the act established a more predictable framework for drug pricing negotiations with the White House, resolving the “policy overhang” that suppressed healthcare stock valuations.
- How is Agentic AI different from the AI healthcare tools used in previous years?
-
In 2024 and 2025, AI in healthcare was primarily “passive,” meaning it could analyse an X-ray or transcribe a note but required a human to initiate every step. In 2026, the industry has moved to Agentic AI – autonomous agents that can plan and execute multi-step tasks. This development includes where an AI agent doesn’t just flag a lab result; it cross-references the patient’s history, drafts a follow-up plan, checks the doctor’s calendar for an appointment slot, and sends a pre-authorised referral to a specialist. Companies successfully deploying these agents are seeing “software-sector-like” margins.
This information is for educational purposes only and should not be taken as investment advice, personal recommendation, or an offer of, or solicitation to, buy or sell any financial instruments.
This material has been prepared without regard to any particular investment objectives or financial situation and has not been prepared in accordance with the legal and regulatory requirements to promote independent research.
Not all of the financial instruments and services referred to are offered by eToro and any references to past performance of a financial instrument, index, or a packaged investment product are not, and should not be taken as, a reliable indicator of future results. The availability of all the above-mentioned products and services may vary by jurisdiction and country.
eToro makes no representation and assumes no liability as to the accuracy or completeness of the content of this guide. Make sure you understand the risks involved in trading before committing any capital. Never risk more than you are prepared to lose.